PTC Therapeutics, Inc.
PTCTBiotechnology
$64.46+2.28%As of Oct 29vs prior close
- Market cap
- $5.4B
- P/E (TTM)
- –
- P/E (FY1)
- 42.5×
- From 52W high
- −28.02%
- EPS (LTM)
- -$1.36
- Revenue (LTM)
- $1.2B
- Net margin
- -9.17%
- Dividend yield
- 0.00%
Nomior Score
56
Steady ProfileSpeculativeTop 36% of the scored universe
Growth54
Quality68
Value58
Momentum39
Resilience52
Growth
+40.20%revenue a year over 9 fiscal years
FY16 $82.7MLTM $1.2B
Connections
Revenue to profitQ3 FY26
The net loss was 14% of revenue, wider by 22 pts on a year.
Who owns it
2funds, 1 tracked portfolio